BRISTOL-MYERS SQUIBB COMPANY Amortization of Other Deferred Charges
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Amortization of Other Deferred Charges of $39.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherAmortizationOfDeferredCharges · last filed 2022-02-09
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for the quarter ending 2021-06-30 was $15.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for the quarter ending 2021-03-31 was $15.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for the quarter ending 2020-12-31 was $14.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for the quarter ending 2020-09-30 was $14.00M, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for fiscal 2021 was $39.00M, a 32.76% decline from fiscal 2020.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for fiscal 2020 was $58.00M, a 0.00% change from fiscal 2019.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for fiscal 2019 was $58.00M, a 1.75% increase from fiscal 2018.
- BRISTOL-MYERS SQUIBB COMPANY amortization of other deferred charges for fiscal 2018 was $57.00M.
| Period end | Amortization of Other Deferred Charges 3 month | Amortization of Other Deferred Charges 6 month | Amortization of Other Deferred Charges 9 month | Amortization of Other Deferred Charges 12 month |
|---|---|---|---|---|
| 2021-12-31 | $39.00M 10-K · filed 2022-02-09 | |||
| 2021-06-30 | $15.00M 10-Q · filed 2021-07-28 | $30.00M 10-Q · filed 2021-07-28 | $44.00M derived: sum of 3 quarters · filed 2022-02-09 | $58.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2021-03-31 | $15.00M 10-Q · filed 2021-04-29 | $29.00M derived: sum of 2 quarters · filed 2022-02-09 | $43.00M derived: sum of 3 quarters · filed 2022-02-09 | $58.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $28.00M derived: sum of 2 quarters · filed 2022-02-09 | $43.00M derived: sum of 3 quarters · filed 2022-02-09 | $58.00M 10-K · filed 2022-02-09 |
| 2020-09-30 | $14.00M 10-Q · filed 2020-11-05 | $29.00M derived: sum of 2 quarters · filed 2021-07-28 | $44.00M 10-Q · filed 2020-11-05 | $58.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-06-30 | $15.00M 10-Q · filed 2021-07-28 | $30.00M 10-Q · filed 2021-07-28 | $44.00M derived: sum of 3 quarters · filed 2022-02-09 | $58.00M derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-03-31 | $15.00M 10-Q · filed 2021-04-29 | $29.00M derived: sum of 2 quarters · filed 2022-02-09 | $43.00M derived: sum of 3 quarters · filed 2022-02-09 | |
| 2019-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $28.00M derived: sum of 2 quarters · filed 2022-02-09 | $58.00M 10-K · filed 2022-02-09 | |
| 2019-09-30 | $14.00M 10-Q · filed 2020-11-05 | $44.00M 10-Q · filed 2020-11-05 | ||
| 2018-12-31 | $57.00M 10-K · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |